6876.TWO LAUNXP Biomedical Co., Ltd
- Market cap
- TWD 889M
- P/E
- -
- P/B
- 2.47x
- ROE
- -75.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2024.
Is 6876.TWO undervalued?
Graham numberThe Graham number of LAUNXP Biomedical Co., Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LAUNXP Biomedical Co., Ltd fundamental analysis
No fundamental analysis for LAUNXP Biomedical Co., Ltd yet.
LAUNXP Biomedical Co., Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LAUNXP Biomedical Co., Ltd
LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients. It develops various drugs, which are in preclinical stage, including LXP5948 for non-small cell lung cancer and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and Virus-like particles for cancer and genetic defect treatment. The company was founded in 2015 and is based in Taichung, Taiwan.
Full company profileLAUNXP Biomedical Co., Ltd financial statements
LAUNXP Biomedical Co., Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 0.00 | 11.0K | 2.48M |
| Gross Profit | 0.00 | 0.00 | 11.0K | 2.29M |
| Operating Income | -34.8M | -43.6M | -81.0M | -82.3M |
| EBITDA | - | -41.1M | -78.4M | -79.6M |
| Net Income | -34.7M | -43.6M | -80.9M | -82.6M |
| EPS | -1.08 | -1.35 | -2.51 | -2.55 |
| Balance Sheet | ||||
| Total Assets | 73.9M | 32.4M | 206M | 124M |
| Total Liabilities | 8.65M | 10.2M | 23.2M | 15.0M |
| Shareholders' Equity | 65.2M | 22.2M | 183M | 109M |
| Cash & Short-term Investments | 34.1M | 15.2M | 180M | 98.4M |
| Cash Flow | ||||
| Operating Cash Flow | -29.0M | -44.2M | -59.1M | -76.7M |
| Capital Expenditure | 4.24M | 804K | 3.32M | 316K |
| Free Cash Flow | -33.2M | -45.0M | -62.5M | -77.0M |
| Ratios | ||||
| ROE | -53.3% | -196.3% | -44.2% | -75.9% |
| ROA | -47.0% | -134.4% | -39.2% | -66.7% |
| Net Profit Margin | - | - | -735,900.0% | -3,325.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
LAUNXP Biomedical Co., Ltd dividends
LAUNXP Biomedical Co., Ltd has not paid dividends in the last 4 fiscal years.
Who owns LAUNXP Biomedical Co., Ltd
Ownership data of LAUNXP Biomedical Co., Ltd is not available yet.
LAUNXP Biomedical Co., Ltd company profile
- Company name
- LAUNXP Biomedical Co., Ltd
- Ticker
- 6876.TWO
- ISIN
- TW0006876006
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- B1 Room, No. 51, Section 2, Taichung, Taiwan, 408
- Phone
- 886 4 2320 5691
- Website
- launxp.com
About LAUNXP Biomedical Co., Ltd
LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients. It develops various drugs, which are in preclinical stage, including LXP5948 for non-small cell lung cancer and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and Virus-like particles for cancer and genetic defect treatment. The company was founded in 2015 and is based in Taichung, Taiwan.
LAUNXP Biomedical Co., Ltd management
2- Dr. Chiu-Heng ChenPresident & Director
- Aileen HsuChief Financial Officer